P4‐127: Exploring the Utility of CSF Neurogranin Levels in An Alzheimer’s Disease Clinical Trial

stratified, multi-modal biomarker assessed AD cases and controls to define a novel array of single nucleotide polymorphism (SNP) markers. This panel, which performed with high levels of accuracy (AUC) in differentiating AD and controls in an independent test set of samples, has now been used for SNP genotyping, using the Affymetrix Axiom Genotyping Technology, of additional clinical samples obtained as part of observational studies. Results: Samples were analysed from amyloid-positive and amyloid-negative aged-matched individuals who were either cognitively normal or previously diagnosed with Mild Cognitive Impairment (MCI). On the basis that amyloid positivity, as determined by positron emission tomography (PET), is considered to represent a significant risk factor for future progression to AD, we have conducted analyses to determine potential relationships between amyloid status and SNP profiles in these groups. Conclusions: The results from these analyses provide indications as to the potential utility of SNP genotyping arrays in the risk profiling of early symptomatic and pre-symptomatic individuals.